Clinical trial • Not applicable • Neurology
Clinical trial in Multiple sclerosis | Refractory multiple sclerosis
Not applicable trial for Multiple sclerosis | Refractory multiple sclerosis. 25 participants.
Overview
- Trial Therapeutic Area
- Neurology
- Trial Disease
- Multiple sclerosis | Refractory multiple sclerosis
- Trial Stage
- Not applicable
Key dates
- Initial CTIS Submission Date
- 28-03-2025
- First CTIS Authorization Date
- 30-06-2025
Trial design
Not applicable trial across 2 sites in Germany.
- Target Sample Size
- 25
- Trial Duration For Participant
- 1845
Eligibility
Recruits 25 Vulnerable population selected; no details on consent or assent provided in the record..
- Vulnerable Population
- Vulnerable population selected; no details on consent or assent provided in the record.
Recruitment
- Planned Sample Size
- 25
- Recruitment Window Months
- 60
Geography
- Total Number Of Sites
- 2
- Total Number Of Participants
- 25
Germany
- Earliest CTIS Part Ii Submission Date
- 30-05-2025
- Latest Decision Or Authorization Date
- 12-11-2025
- Processing Time Days
- 166
- Number Of Sites
- 2
- Number Of Participants
- 25
Sites
- Site Name
- Charite Universitaetsmedizin Berlin KöR
- Department Name
- Klinik für Neurologie mit Experimenteller Neurologie
- Principal Investigator Name
- Volker Siffrin
- Principal Investigator Email
- volker.siffrin@charite.de
- Contact Person Name
- Volker Siffrin
- Contact Person Email
- volker.siffrin@charite.de
- Site Name
- University Medical Center Hamburg-Eppendorf
- Department Name
- Neurology
- Principal Investigator Name
- Francis Ayuketang Ayuk
- Principal Investigator Email
- ayuketang@uke.de
- Contact Person Name
- Francis Ayuketang Ayuk
- Contact Person Email
- ayuketang@uke.de
Sponsor
Primary sponsor
- Full Name
- Miltenyi Biomedicine GmbH
- Organisation Type
- Pharmaceutical company
- Country Of Registered Address
- Germany
Related trials
Other published trials that may interest you.
- OCRELIZUMAB for Relapsing multiple sclerosis | Relapsing-remitting multiple sclerosis | Secondary progressive multiple sclerosis (active)
- CENOBAMATE for Partial-onset (focal) seizures
- Ocrelizumab for Relapsing multiple sclerosis | Relapsing-remitting multiple sclerosis | Active secondary progressive multiple sclerosis
- Clinical trial in Parkinson's disease
- Tenecteplase for Acute ischaemic stroke due to basilar artery occlusion | Posterior circulation ischaemic stroke